VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. The company is headquartered in San Diego, California.
| Revenue (TTM) | 142,000 |
| Gross Profit (TTM) | $-3.78M |
| EBITDA | $-11.22M |
| Operating Margin | -10577.00% |
| Return on Equity | -51.10% |
| Return on Assets | -132.50% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $1.70 |
| Price-to-Book | 0.64 |
| Price-to-Sales (TTM) | 18.43 |
| EV/Revenue | 1.181 |
| EV/EBITDA | -0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 8.30% |
| Shares Outstanding | $2.89M |
| Float | $2.33M |
| % Insiders | 14.80% |
| % Institutions | 7.69% |
Volatility is currently expanding
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)
VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results VivoSim's NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
